RETRACTED ARTICLE: MicroRNA-29 mediates anti-inflammatory effects and alleviation of allergic responses and symptoms in mice with allergic rhinitis

Abstract

Background To investigate the role of microRNA-29 (miR-29) in mice with allergic rhinitis (AR) and its underlying mechanism. Methods AR model was established in BALB/c mice by intraperitoneal sensitization and intranasal challenge with ovalbumin (OVA). miRNA expression was examined in the nasal mucosa tissues of mice and patients with AR, and miRNA-29 was found to be downregulated. To unveil the role of miRNA-29 in AR, it was overexpressed in the nasal mucosa of AR mice by intranasal administration of miRNA-29 agomir. The symptoms of nasal rubbing and sneezing were recorded and evaluated. miR-29 expression, OVA-specific immunoglobulin E (IgE) concentration, pro-inflammatory cytokines levels, eosinophils number, and cleaved caspase-3 and CD276 expression were examined in nasal mucosa tissues and nasal lavage fluid (NALF) by qRT-PCR, ELISA, hematoxylin and eosin staining, western blotting, or immunohistochemistry, respectively. TUNEL assay was used to analyze nasal mucosa cells apoptosis. Results Decreased expression of miR-29 was observed in AR, the symptoms of which were alleviated by overexpressing miR-29. In addition, overexpression of miR-29 markedly reduced the concentration of OVA-specific IgE, the levels of IL-4, IL-6, IL-10, and IFN-γ, the pathological alterations and eosinophils infiltration in the nasal mucosa. Furthermore, restoration of miR-29 expression reduced nasal mucosa cell apoptosis. Moreover, overexpression of miR-29 significantly attenuated CD276 mRNA and protein levels in nasal mucosa cells. Conclusion MiR-29 mediated antiallergic effects in OVA-induced AR mice by decreasing inflammatory response, probably through targeting CD276. MiRNA-29 may serve as a potential novel therapeutic target for the treatment of AR.

Noncoding RNAs and Virus and Treatment in Allergic Rhinitis

“…Down-regulated CD276 Decreasing inflammatory response [37]. 4 Evidence-Based Complementary and Alternative Medicine IL-13 and gm-csf Linc00632 inhibited IL-13-induced GM-CSF, eotaxin, and MUAC5AC production in IL-13-treated NECs by targeting miR-498 [44].…”

miR-224-5p Attenuates Allergic Responses in Mice with Allergic Rhinitis by Modulating the Th1/Th2 Response

“…miRNAs have been shown to be joint regulators of AR development [ 27 ]. For example, miR-29 suppresses allergic reactions and symptoms in mice with AR [ 28 ]. miRNA-345-5p attenuates AR progression through TLR4/NF- κ B pathway-mediated inflammation [ 29 ].…”

miR-146a-5p Attenuates Allergic Airway Inflammation by Inhibiting the NLRP3 Inflammasome Activation in Macrophages

“…The experimental mice were randomly divided into the following 6 groups with 12 mice in each group: (1) OVA group: mice were intraperitoneally injected with 0.2 mL mixture (100 μg OVA [Sigma, St. Louis, MO, USA] emulsified in 1 mg aluminum hydroxide (Pierce, Rockford, IL, USA]) on days 0-14. Every day from days 15-22, the mice were given 5% OVA using an ultrasonic atomizer through the airway for 30 min to establish the mouse model of allergic asthma; (2) CTR group: mice were treated with an equal amount of normal saline instead of OVA; (3) OVA + miRago group: every day from days 15-22, 20 μL 5 pmol/μL miR-146a-5p agomir (GeneChem, Shanghai, China) was injected intranasally 3 h before stimulation with an ultrasonic atomizer [22]; (4) OVA + agomir NC (negative control) group: every day from days 15-22, 20 μL 5 pmol/μL agomir NC (GeneChem) was injected intranasally 3 h before stimulation with an ultrasonic atomizer; (5) OVA + miR-ago + oe (overexpressed)-TIRAP group: every day from days 15-22, mice were treated with miR-146a-5p agomir and simultaneously intraperitoneally injected with 10 μg/g TIRAP overexpression plasmid (oe-TIRAP) 3 h before stimulation with an ultrasonic atomizer [23]; (6) OVA + miR-ago + oe-NC group: every day from days 15-22, mice were treated with miR-146a-5p agomir and simultaneously intraperitoneally injected with 10 μg/g empty plasmid (oe-NC) 3 h before stimulation with an ultrasonic atomizer. The oe-TIRAP and oe-NC plasmids were all purchased from Thermo Fisher (Waltham, MA, USA).…”